

Scancell

Successful upsized placing raises over £10m

1 December 2023

- Scancell has raised £10.7m through an upsized Placing to new and existing institutional shareholders through an accelerated bookbuild that successfully raised £10.6m (gross) overnight, and a Subscription for Board members which raised £80k, all at an issue price of 11.0p. An additional up to £2m may also be raised through an Open Offer to all qualifying shareholders, based on 1 share for each 45 qualifying shares, with an option for shareholders applying for their full entitlement to also apply for additional shares through an Excess Application Facility. The Open Offer circular is expected to be issued on or around 4 December, with the Open Offer shares expected to be admitted for trading on or around 20 December. Shares from the Placing component are expected to be admitted on or around 5 December.
- The capital raise follows a series of encouraging clinical results across Scancell's pipeline. Impressive data in September from the Phase II [SCOPE](#) study demonstrated SCIB1 in combination with the checkpoint inhibitors (CPIs) ipilimumab (Yervoy) and nivolumab (Opdivo) in advanced melanoma achieved an objective response rate (ORR) of 82%, with no increase in toxicity. This compares favourably with currently achievable ORRs (doublet CPI therapy response rates are around 48-58%). In November two further responders (11 out of 13 patients) brought the ORR to 85% and, importantly, one patient achieved a complete response.
- SCOPE is now in the second stage, recruiting another 27 patients (for a total of 43 patients). The aim is to achieve 18 responses (ie 27 responses in total) to demonstrate SCIB1 can exceed currently achievable ORRs. The strength of the initial results means this stage has a 90% probability of success, with data expected in H124. SCOPE will also transition in Q124 to the improved second-generation iSCIB1+ construct, which is enhanced with AvidiMab. This is more potent and capable of addressing all melanoma patients.
- The Moditope therapeutic vaccine platform is also progressing well. ModiFY is an adaptive 100+ patient open label Phase I/II study exploring Modi-1 alone and in combination with CPIs in a variety of hard-to-treat cancers. Encouraging results have been seen in a number of settings. The clean safety profile means ModiFY is moving into the expansion cohorts, including with CPIs. Early clinical data are expected to become available through 2024.

Price	10.98p
Market Cap	£91.8m
Primary exchange	AIM
Sector	Healthcare
Company Codes	SCLP.L
Corporate client	Yes

Company description:

Scancell is a clinical-stage immuno-oncology specialist that has four broadly applicable technology platforms. Two are therapeutic vaccines, Moditope and ImmunoBody, and two are antibody based, GlyMab and AvidiMab.

Analysts

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Trinity Delta view: Scancell's successful upsized >£10m placing removes financial uncertainty and, assuming similar success in the Open Offer, means the cash runway now extends to late 2025. This covers the important clinical milestones for both SCIB1 and Modi-1 programmes and could be extended further through the partnering or out-licensing of selected programmes from the GlyMab and AvidiMab antibody platforms. As usual in such situations we suspend our valuation and forecasts, but for context our last published rNPV based valuation for Scancell was £300.1m, equivalent to 36.7p/share.

Philippa Gardner

pgardner@trinitydelta.org
+44 (0) 20 3637 5042

Lala Gregorek

lgregorek@trinitydelta.org
+44 (0) 20 3637 5043

Franc Gregori

fgregori@trinitydelta.org
+44 (0) 20 3637 5041

Disclaimer

Trinity Delta Research Limited ("TDRL"; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited ("ED"). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves ('issuer financed research') and as such is not deemed to be independent, as defined by the FCA, but is 'objective' in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2023 Trinity Delta Research Limited. All rights reserved.

More information is available on our website: www.trinitydelta.org